Tedizolid

Tedizolid
Clinical data
Trade names	Sivextro
Other names	TR-700, torezolid
AHFS/Drugs.com	Monograph
MedlinePlus	a614038
License data	US DailyMed: Tedizolid;
Routes of; administration	By mouth, intravenous
ATC code	J01XX11 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	91%
Protein binding	70–90%
Elimination half-life	12 hours
Excretion	Feces
Identifiers
	IUPAC name (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one;
CAS Number	856866-72-3 ; Phosphate: 856867-55-5 ;
PubChem CID	11234049;
DrugBank	DB09042 ;
ChemSpider	9409096 ;
UNII	97HLQ82NGL; Phosphate: O7DRJ6R4DW ;
KEGG	D09685 ; Phosphate: D09686 ;
ChEBI	CHEBI:82717 ;
ChEMBL	ChEMBL1257051 ;
CompTox Dashboard (EPA)	DTXSID10234975 ;
ECHA InfoCard	100.249.430
Chemical and physical data
Formula	C17H15FN6O3
Molar mass	370.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4O[C@H](CN4c3cc(F)c(c1ccc(nc1)c2nn(nn2)C)cc3)CO;
	InChI InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1 ; Key:XFALPSLJIHVRKE-GFCCVEGCSA-N ;
	(what is this?) (verify)

Tedizolid, sold under the brand name Sivextro (by Merck) is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).

The most common side effects include nausea (feeling sick), headache, diarrhoea and vomiting. These side effects were generally of mild or moderate severity.

Tedizolid was approved for medical use by the FDA in the United States in June 2014, and for medical use in the European Union by EMA in March 2015.